IN2014MN02393A - - Google Patents
Info
- Publication number
- IN2014MN02393A IN2014MN02393A IN2393MUN2014A IN2014MN02393A IN 2014MN02393 A IN2014MN02393 A IN 2014MN02393A IN 2393MUN2014 A IN2393MUN2014 A IN 2393MUN2014A IN 2014MN02393 A IN2014MN02393 A IN 2014MN02393A
- Authority
- IN
- India
- Prior art keywords
- derivatives
- intreating
- diseases
- modulation
- processes
- Prior art date
Links
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 abstract 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650325P | 2012-05-22 | 2012-05-22 | |
| GB201209015A GB201209015D0 (en) | 2012-05-22 | 2012-05-22 | Novel compounds |
| US201361773710P | 2013-03-06 | 2013-03-06 | |
| PCT/GB2013/051335 WO2013175205A1 (en) | 2012-05-22 | 2013-05-22 | Novel Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02393A true IN2014MN02393A (enEXAMPLES) | 2015-08-21 |
Family
ID=46546493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2393MUN2014 IN2014MN02393A (enEXAMPLES) | 2012-05-22 | 2013-05-22 |
Country Status (27)
| Country | Link |
|---|---|
| US (7) | US9309254B2 (enEXAMPLES) |
| EP (3) | EP3106464B1 (enEXAMPLES) |
| JP (3) | JP6169687B2 (enEXAMPLES) |
| KR (2) | KR102161101B1 (enEXAMPLES) |
| CN (2) | CN107344942B (enEXAMPLES) |
| AU (3) | AU2013265001B2 (enEXAMPLES) |
| BR (1) | BR112014029280B1 (enEXAMPLES) |
| CA (1) | CA2873956C (enEXAMPLES) |
| CY (2) | CY1118274T1 (enEXAMPLES) |
| DK (2) | DK3106464T3 (enEXAMPLES) |
| EA (1) | EA025579B1 (enEXAMPLES) |
| ES (3) | ES2782088T3 (enEXAMPLES) |
| GB (1) | GB201209015D0 (enEXAMPLES) |
| HR (2) | HRP20161349T1 (enEXAMPLES) |
| HU (2) | HUE049445T2 (enEXAMPLES) |
| IL (4) | IL235805A (enEXAMPLES) |
| IN (1) | IN2014MN02393A (enEXAMPLES) |
| LT (2) | LT3106464T (enEXAMPLES) |
| MX (1) | MX355303B (enEXAMPLES) |
| PL (2) | PL3106464T3 (enEXAMPLES) |
| PT (2) | PT3106464T (enEXAMPLES) |
| RS (2) | RS55415B1 (enEXAMPLES) |
| SG (2) | SG11201407755UA (enEXAMPLES) |
| SI (2) | SI2861602T1 (enEXAMPLES) |
| SM (2) | SMT202000210T1 (enEXAMPLES) |
| WO (2) | WO2013175206A1 (enEXAMPLES) |
| ZA (1) | ZA201408253B (enEXAMPLES) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| US20200255438A1 (en) * | 2017-09-28 | 2020-08-13 | Biogen Inc. | Novel salts |
| EP3694510A4 (en) | 2017-10-10 | 2021-06-30 | Biogen Inc. | SPIRO DERIVATIVE PREPARATION PROCESS |
| WO2022133097A1 (en) * | 2020-12-17 | 2022-06-23 | Biogen Ma Inc. | Synthesis of compounds that modulate use-dependent voltage-gated sodium channels |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100564381C (zh) * | 2002-07-05 | 2009-12-02 | 塔加西普特公司 | N-芳基二氮杂螺环化合物及其制备方法和制备药物的用途 |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| US8143306B2 (en) | 2005-10-10 | 2012-03-27 | Convergence Pharmaceuticals Limited | Methods of treating bipolar disorders |
| US7855218B2 (en) | 2005-10-10 | 2010-12-21 | Convergence Pharmaceuticals Limited | Compounds |
| GB0520578D0 (en) * | 2005-10-10 | 2005-11-16 | Glaxo Group Ltd | Novel compounds |
| KR20080059292A (ko) * | 2005-10-12 | 2008-06-26 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 이온 채널 조절인자로서의 바이페닐 유도체 |
| WO2007084314A2 (en) * | 2006-01-12 | 2007-07-26 | Incyte Corporation | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| US20110294842A9 (en) | 2006-10-12 | 2011-12-01 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| MX2009003874A (es) * | 2006-10-12 | 2009-04-22 | Xenon Pharmaceuticals Inc | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. |
| GB0701366D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| GB0701365D0 (en) | 2007-01-24 | 2007-03-07 | Glaxo Group Ltd | Novel pharmaceutical compositions |
| CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
| GB0706630D0 (en) * | 2007-04-04 | 2007-05-16 | Glaxo Group Ltd | Novel compounds |
| AR077252A1 (es) * | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US8759542B2 (en) | 2009-09-14 | 2014-06-24 | Convergence Pharmaceuticals Limited | Process for preparing alpha-carboxamide derivatives |
| GB201122113D0 (en) * | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| WO2013142331A1 (en) * | 2012-03-21 | 2013-09-26 | Interdigital Patent Holdings, Inc. | Sponsoring of a mobile station session by another mobile station in a wireless network |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| GB201209670D0 (en) | 2012-05-31 | 2012-07-18 | Convergence Pharmaceuticals | Novel compounds |
-
2012
- 2012-05-22 GB GB201209015A patent/GB201209015D0/en not_active Ceased
-
2013
- 2013-05-22 PT PT161777008T patent/PT3106464T/pt unknown
- 2013-05-22 MX MX2014014274A patent/MX355303B/es active IP Right Grant
- 2013-05-22 EA EA201492169A patent/EA025579B1/ru unknown
- 2013-05-22 HU HUE16177700A patent/HUE049445T2/hu unknown
- 2013-05-22 BR BR112014029280-9A patent/BR112014029280B1/pt not_active IP Right Cessation
- 2013-05-22 ES ES16177700T patent/ES2782088T3/es active Active
- 2013-05-22 EP EP16177700.8A patent/EP3106464B1/en active Active
- 2013-05-22 HR HRP20161349TT patent/HRP20161349T1/hr unknown
- 2013-05-22 AU AU2013265001A patent/AU2013265001B2/en not_active Ceased
- 2013-05-22 EP EP13725438.9A patent/EP2861602B1/en active Active
- 2013-05-22 CN CN201710522297.1A patent/CN107344942B/zh not_active Expired - Fee Related
- 2013-05-22 WO PCT/GB2013/051336 patent/WO2013175206A1/en active Application Filing
- 2013-05-22 US US14/403,480 patent/US9309254B2/en not_active Expired - Fee Related
- 2013-05-22 WO PCT/GB2013/051335 patent/WO2013175205A1/en active Application Filing
- 2013-05-22 PL PL16177700T patent/PL3106464T3/pl unknown
- 2013-05-22 ES ES13725439.7T patent/ES2602308T3/es active Active
- 2013-05-22 EP EP13725439.7A patent/EP2861594B1/en not_active Not-in-force
- 2013-05-22 IN IN2393MUN2014 patent/IN2014MN02393A/en unknown
- 2013-05-22 CA CA2873956A patent/CA2873956C/en active Active
- 2013-05-22 JP JP2015513266A patent/JP6169687B2/ja not_active Expired - Fee Related
- 2013-05-22 LT LTEP16177700.8T patent/LT3106464T/lt unknown
- 2013-05-22 PL PL13725438T patent/PL2861602T3/pl unknown
- 2013-05-22 SI SI201330339A patent/SI2861602T1/sl unknown
- 2013-05-22 PT PT137254389T patent/PT2861602T/pt unknown
- 2013-05-22 SI SI201331705T patent/SI3106464T1/sl unknown
- 2013-05-22 SG SG11201407755UA patent/SG11201407755UA/en unknown
- 2013-05-22 ES ES13725438.9T patent/ES2602193T3/es active Active
- 2013-05-22 RS RS20160960A patent/RS55415B1/sr unknown
- 2013-05-22 SG SG10201703527WA patent/SG10201703527WA/en unknown
- 2013-05-22 KR KR1020147035444A patent/KR102161101B1/ko not_active Expired - Fee Related
- 2013-05-22 SM SM20200210T patent/SMT202000210T1/it unknown
- 2013-05-22 US US14/403,473 patent/US9376445B2/en not_active Expired - Fee Related
- 2013-05-22 JP JP2015513267A patent/JP2015517562A/ja not_active Withdrawn
- 2013-05-22 DK DK16177700.8T patent/DK3106464T3/da active
- 2013-05-22 RS RS20200393A patent/RS60368B1/sr unknown
- 2013-05-22 CN CN201380038180.6A patent/CN104640867B/zh not_active Expired - Fee Related
- 2013-05-22 KR KR1020207027461A patent/KR20200113027A/ko not_active Ceased
- 2013-05-22 LT LTEP13725438.9T patent/LT2861602T/lt unknown
- 2013-05-22 HU HUE13725438A patent/HUE031664T2/en unknown
- 2013-05-22 DK DK13725438.9T patent/DK2861602T3/en active
-
2014
- 2014-11-11 ZA ZA2014/08253A patent/ZA201408253B/en unknown
- 2014-11-20 IL IL235805A patent/IL235805A/en active IP Right Grant
-
2016
- 2016-02-15 US US15/043,920 patent/US20160184306A1/en not_active Abandoned
- 2016-05-25 US US15/163,845 patent/US9737536B2/en active Active
- 2016-11-09 CY CY20161101143T patent/CY1118274T1/el unknown
- 2016-11-21 SM SM201600421T patent/SMT201600421B/it unknown
-
2017
- 2017-03-01 AU AU2017201421A patent/AU2017201421B2/en not_active Ceased
- 2017-04-30 IL IL252033A patent/IL252033B/en active IP Right Grant
- 2017-06-28 JP JP2017125716A patent/JP6378404B2/ja not_active Expired - Fee Related
- 2017-07-11 US US15/646,552 patent/US10010551B2/en active Active
-
2018
- 2018-03-07 AU AU2018201653A patent/AU2018201653B2/en not_active Ceased
- 2018-06-27 US US16/019,886 patent/US10485801B2/en not_active Expired - Fee Related
-
2019
- 2019-10-17 US US16/655,970 patent/US20200289508A1/en not_active Abandoned
- 2019-12-11 IL IL271330A patent/IL271330B/en active IP Right Grant
-
2020
- 2020-04-06 HR HRP20200580TT patent/HRP20200580T1/hr unknown
- 2020-04-07 CY CY20201100326T patent/CY1123044T1/el unknown
-
2021
- 2021-02-02 IL IL280595A patent/IL280595A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502839B1 (en) | Antiviral compounds | |
| IN2014MN02459A (enEXAMPLES) | ||
| CR20150370A (es) | Compuestos antivirales | |
| CR20140405A (es) | Apoptosis señal reguladores del inhibidor de quinasa | |
| NZ705213A (en) | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof | |
| MY180903A (en) | C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof | |
| ZA201507627B (en) | P2x7 modulators | |
| MX346375B (es) | Antagonistas de espiro-oxindol de mdm2. | |
| MX2011008864A (es) | Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales. | |
| PH12014502414A1 (en) | Novel compounds | |
| SG190785A1 (en) | Antiviral compounds | |
| ECSP11011517A (es) | Compuestos antivirales | |
| MY177031A (en) | Tetrahydropyridopyrazines modulators of gpr6 | |
| MX348862B (es) | Derivados c4-monometil triterpenoides y sus metodos de uso. | |
| EP2938616A4 (en) | PROCESS FOR THE PREPARATION OF TOFACITINIB AND INTERMEDIATES | |
| MX2017003254A (es) | 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina. | |
| EA201390894A1 (ru) | Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления | |
| WO2013165921A3 (en) | Therapeutic use of chardonnay seed products | |
| IN2014MN01469A (enEXAMPLES) | ||
| HK1208677A1 (zh) | 具有咪唑-聯苯-咪唑核心之抗病毒化合物 | |
| CR20140435A (es) | Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos | |
| WO2013108105A3 (en) | Novel solvates of darunavir | |
| IN2014MN02393A (enEXAMPLES) | ||
| MX2019011265A (es) | Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2. | |
| MX348841B (es) | Derivados de pirimidooxazocina como inhibidores de mtor. |